- CORE D Core D offers world-class genomics and proteomics services to the members of the Program. The Next Generation sequencing facility was strongly supported by CSHL during the last five years, and it has extended its capability in short (Illumina HiSeq2500, MiSeq and NextSeq) and long read technologies (Pacific Biosciences, Oxford Nanopore). Core D offers an extensive array of sequencing applications, including but not limited to RNA- Seq, Iso-Seq, whole genome sequencing, targeted sequencing (exomes, gene set, and amplicons), ChIP-Seq and single-cell sequencing. For proteomics, the Core offers protein identification, protein complex identification following IP, quantitative proteomics with iTRAQ and a panel of small molecule and metabolite screens. The Core will continue working with members to develop new sequencing and proteomics applications, including in the area of long sequencing reads and single-cell sequencing, The Core will also offer experimental design support, sequencing project management and sequencing QC analysis to the investigators.

Public Health Relevance

- CORE D Genomics and proteomic are essential tools in cancer research. Core D provides services in DNA sequencing to identify changes in gene expression, epigenetics and DNA mutations driving the growth and maintenance of cancer. Mass spectrometry identifies proteins bound to essential cellular complexes, deepening our understanding of cancer cell growth and gene regulation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA013106-48
Application #
9851828
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2020-02-01
Budget End
2021-01-31
Support Year
48
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Cold Spring Harbor Laboratory
Department
Type
DUNS #
065968786
City
Cold Spring Harbor
State
NY
Country
United States
Zip Code
11724
Tarumoto, Yusuke; Lu, Bin; Somerville, Tim D D et al. (2018) LKB1, Salt-Inducible Kinases, and MEF2C Are Linked Dependencies in Acute Myeloid Leukemia. Mol Cell 69:1017-1027.e6
Xu, Yali; Milazzo, Joseph P; Somerville, Tim D D et al. (2018) A TFIID-SAGA Perturbation that Targets MYB and Suppresses Acute Myeloid Leukemia. Cancer Cell 33:13-28.e8
Huang, Yu-Han; Klingbeil, Olaf; He, Xue-Yan et al. (2018) POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. Genes Dev 32:915-928
Livshits, Geulah; Alonso-Curbelo, Direna; Morris 4th, John P et al. (2018) Arid1a restrains Kras-dependent changes in acinar cell identity. Elife 7:
Tiriac, Hervé; Belleau, Pascal; Engle, Dannielle D et al. (2018) Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov 8:1112-1129
Bhagwat, Anand S; Lu, Bin; Vakoc, Christopher R (2018) Enhancer dysfunction in leukemia. Blood 131:1795-1804
Banito, Ana; Li, Xiang; Laporte, Aimée N et al. (2018) The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma. Cancer Cell 34:346-348
Skucha, Anna; Ebner, Jessica; Schmöllerl, Johannes et al. (2018) MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity. Nat Commun 9:1983
Banito, Ana; Li, Xiang; Laporte, Aimée N et al. (2018) The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma. Cancer Cell 33:527-541.e8
Lin, Kuan-Ting; Ma, Wai Kit; Scharner, Juergen et al. (2018) A human-specific switch of alternatively spliced AFMID isoforms contributes to TP53 mutations and tumor recurrence in hepatocellular carcinoma. Genome Res :

Showing the most recent 10 out of 610 publications